A tiny Cambridge company targeting new treatments for cancer, has struck a major deal in China. As Prime Minister David Cameron’s trade mission to China gets underway, Sareum, based at Pampisford, has signed an agreement with Hebei Medical University Biomedical Engineering Center (HMUBEC) to advance its new treatment for the most common form of adult leukaemia and various other cancers. HMUBEC now has exclusive rights to carry out pre-clinical and clinical studies across China so that Aurora can be sold there. Sareum, which has just two full-time people, will receive a “significant” milestone payment when the drug is authorised and up to 15% of operating profit from sales. In addition, the Chinese will licence back to Sareum all the data involved in the process so that the Pampisford company can push ahead with the drug in the rest of the world, with HMUBEC taking 10%. A leader in its field, Hebei Medical University Science & Technology General Company, within which HMUBEC sits as an independent research centre, has successfully developed more than 85 drugs and medical devices for the Chinese market since it began in 1992. The Sareum drug controls cell division and has already shown promise in trials. “This agreement provides us with significant additional resource, exposure to a major market and the flexibility to undertake our own independent research using HMUBEC’s findings at any point in the development programme,” said Dr Tim Mitchell, chief executive of Sareum. “HMUBEC also has the capability and resources to advance the drug programme from pre-clinical all the wayn through clinical trials and onto the Chinese market. “We believe all this provides a good balance of risk and reward for our shareholders and we look forward to working closely with HMUBEC.” Prof Donggang Liu of the Hebei Medical University Science & Technology General Company said: “We have been very impressed with the results of the studies undertaken on Sareum’s Aurora+FLT3 programme so far and we have real confidence in the programme’s potential to develop a world class drug to treat several forms of blood cancer. “We have significant resources and expertise to expedite this research programme, and we look forward to starting work on this very exciting compound.SHARE PRICE PREDICTION OF 4.5P BY 2015
Aurora Kinases Aurora kinases A and B are required for cells to both enter and proceed through mitosis, which is the process by which copies of the duplicated DNA chromosomes are segregated into two daughter cells. Moreover, Aurora kinases are over-expressed in a variety of cancers including pancreatic, ovarian, colon, breast, liver, lung, thyroid and bladder cancer. These cellular proteins therefore represent attractive targets for treating a wide range of cancers. FLT3 Kinase Fms-Like Tyrosine Kinase 3 (FLT3) is highly expressed in most acute leukaemias. Its ligand, FLT3-L, stimulates the proliferation of hematopoietic stem progenitor and dendritic cells. FLT-3 is expressed at high levels in acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). FLT-3/ITD (internal tandem duplication) mutation occurs in 15% to 35% of AML patients and promotes constitutive activation of the FLT-3 receptor. AML patients carrying the ITD mutations are found to have a decreased overall survival compared with patients without ITD mutations. Inhibition of FLT3 is therefore expected to be an effective strategy for the treatment of AML and potentially other leukaemias. More information about this programmes can be found here: this is in pre-clinical and clinical trials in china with hbei and we shall be getting news soon PATIENCE....HOLD HOLD HOLD
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.